Open Access

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells

  • Authors:
    • Ludovica Taglieri
    • Francesca De Luliis
    • Anna Giuffrida
    • Sabrina Giantulli
    • Ida Silvestri
    • Susanna Scarpa
  • View Affiliations

  • Published online on: July 3, 2023     https://doi.org/10.3892/ol.2023.13938
  • Article Number: 352
  • Copyright : © Taglieri et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Oncol Lett 14: [Related article:] 3832–3838, 2017; DOI: 10.3892/ol.2017.6597

Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the β-actin western blot control data shown in Fig. 2A and B on p. 3836 were strikingly similar, even though the images appeared to have been horizontally flipped comparing between the two figure parts. In addition, certain of the caspase-8 data shown in Fig. 1D on p. 3825 and in Fig. 2B appeared strikingly to be similar, again with the apparent horizontal flipping of the bands shown in adjacent lanes within Fig. 1D itself.

After having conducted an independent investigation of these figures in the Editorial Office, the Editor of Oncology Letters has decided that this paper should be retracted from the Journal on account of a lack of confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience caused.

Related Articles

Journal Cover

August-2023
Volume 26 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Taglieri L, De Luliis F, Giuffrida A, Giantulli S, Silvestri I and Scarpa S: [Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. Oncol Lett 26: 352, 2023
APA
Taglieri, L., De Luliis, F., Giuffrida, A., Giantulli, S., Silvestri, I., & Scarpa, S. (2023). [Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. Oncology Letters, 26, 352. https://doi.org/10.3892/ol.2023.13938
MLA
Taglieri, L., De Luliis, F., Giuffrida, A., Giantulli, S., Silvestri, I., Scarpa, S."[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells". Oncology Letters 26.2 (2023): 352.
Chicago
Taglieri, L., De Luliis, F., Giuffrida, A., Giantulli, S., Silvestri, I., Scarpa, S."[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells". Oncology Letters 26, no. 2 (2023): 352. https://doi.org/10.3892/ol.2023.13938